Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis

[1] Menezes AM(2005)Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study Lancet 366 1875-81

[2] Perez-Padilla R(2012)Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2163-96

[3] Jardim JR(2006)Projections of global mortality and burden of disease from 2002 to 2030 PLoS Med 3 133-42

[4] Muiño A(2006)Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study Chest 130 847-52

[5] Lopez MV(2002)Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease Thorax 57 959-67

[6] Valdivia G(1996)Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) Am J Respir Crit Care Med 154 1128-38

[7] Vos T(2010)Susceptibility to exacerbation in chronic obstructive pulmonary disease N Engl J Med 363 351-70

[8] Flaxman AD(1998)Phosphodiesterase isozymes: molecular targets for novel antiasthma agents Am J Respir Crit Care Med 157 56-66

[9] Naghavi M(2012)Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease Clin Ther 34 563-71

[10] Lozano R(2005)Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial Lancet 366 83-9

[1] Menezes AM(2005)Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study Lancet 366 1875-81

[2] Perez-Padilla R(2012)Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2163-96

[3] Jardim JR(2006)Projections of global mortality and burden of disease from 2002 to 2030 PLoS Med 3 133-42

[4] Muiño A(2006)Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study Chest 130 847-52

[5] Lopez MV(2002)Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease Thorax 57 959-67

[6] Valdivia G(1996)Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) Am J Respir Crit Care Med 154 1128-38

[7] Vos T(2010)Susceptibility to exacerbation in chronic obstructive pulmonary disease N Engl J Med 363 351-70

[8] Flaxman AD(1998)Phosphodiesterase isozymes: molecular targets for novel antiasthma agents Am J Respir Crit Care Med 157 56-66

[9] Naghavi M(2012)Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease Clin Ther 34 563-71

[10] Lozano R(2005)Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial Lancet 366 83-9